Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats.
Treatment of rats for 18 months with trifluoperazine increased [Met5]- and [Leu5]enkephalin and neurotensin content in striatum and nucleus accumbens. However, in substantia nigra the content of [Met5]enkephalin was decreased, [Leu5]enkephalin unchanged and that of neurotensin increased. Administration of L-DOPA plus carbidopa, bromocriptine or pergolide for 12 months decreased [Met5]enkephalin (except bromocriptine) and neurotensin, but not [Leu5]enkephalin, levels in striatum. L-DOPA decreased and bromocriptine increased neurotensin levels in substantia nigra. But neurotensin levels in nucleus accumbens were unaffected.
D000818:Animals; D001479:Basal Ganglia / Q000378:metabolism*; D001971:Bromocriptine / Q000494:pharmacology; D002230:Carbidopa / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D004743:Enkephalin, Leucine / Q000378:metabolism*; D004744:Enkephalin, Methionine / Q000378:metabolism*; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D009496:Neurotensin / Q000378:metabolism*; D010479:Pergolide / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014268:Trifluoperazine / Q000494:pharmacology
D018492:Dopamine Antagonists; D014268:Trifluoperazine; D010479:Pergolide; D009496:Neurotensin; D001971:Bromocriptine; D007980:Levodopa; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; D002230:Carbidopa; D004298:Dopamine